Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Section Content Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail
-

Arixtra (fondaparinux sodium) injections

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – March 2010

 

Summary View

 

USE IN SPECIFIC POPULATIONS

Pediatric Use
  • Safety and effectiveness of Arixtra in pediatric patients have not been established. Because risk for bleeding during treatment with Arixtra is increased in adults who weigh <50 kg, bleeding may be a particular safety concern for use of Arixtra in the pediatric population.

 

-
-